CCCC C4 Therapeutics, Inc.

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

$7.15  -0.12 (-1.65%)
As of 06/28/2022 15:59:56 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/01/2020
Outstanding shares:  48,797,226
Average volume:  899,766
Market cap:   $344,996,388
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKX9NQ0

---

Valuation   (See tab for details)

---

PE ratio:   -3.65
PB ratio:   0.95
PS ratio:   7.50
Return on equity:   -25.94%
Net income %:   -205.47%